“…The role of chemical modifications and protein engineering in improving the effectiveness of medicines is also discussed. Currently, as an alternative to bacterial L-ASNases with chemotherapeutic use, several type II bacterial enzymes are under consideration: Thermus thermophiles , Proteus vulgaris , Pseudomonas fluorescens , Serratia marcescens , Erwinia aroidea , Aspergillus terreus , Mycobacterium tuberculosis , Yersinia pseudotuberculosis , recombinant Saccharomyces cerevisiae , Halomonas elongata , Sarocladium strictum , Streptomyces rochei , Aspergillus terreus , Fusarium culmorum and Zymomonas mobilis [ 62 , 138 , 139 , 140 , 141 , 142 ]. They all have antiproliferative activities toward cancer cells.…”